Key clinical trials of sacituzumab govitecan

Drug(s)	Indication	Phase	Status	Location(s)	Identifier	Sponsors
Sacituzumab govitecan, chemotherapy	HR+/HER–mBC	III	Recruiting	Multinational	NCT03901339, EudraCT2018-004201-33, IMMU132-09, TROPICS-02	Immunomedics
Sacituzumab govitecan + immunotherapy	mTNBC	I/II	Recruiting	Multinational	NCT03424005, EudraCT2017-002038-21, CO40115, MORPHEUS-TNBC	Roche
Sacituzumab govitecan + Talazoparib	mTNBC	I/II	Recruiting	USA	NCT04039230, 19-239	Massachusetts General Hospital
Sacituzumab govitecan, chemotherapy	mTNBC	III	Active, no longer recruiting	Multinational	NCT02574455, EudraCT2017-003019-21, IMMU132-05, ASCENT	Immunomedics
Sacituzumab govitecan	Localised TNBC	II	Not yet recruiting	USA	NCT04230109, 19-578, NeoSTAR	Massachusetts General Hospital
Sacituzumab govitecan	Endometrial cancer	II	Recruiting	USA	NCT04251416, 2000026850	Yale
Sacituzumab govitecan	Epithelial cancers	I/II	Active, no longer recruiting	USA	NCT01631552, VICCPHI1394, IM-T-IMMU132-01, IMMU-132-01	Immunomedics
Sacituzumab govitecan	Prostate cancer	II	Recruiting	USA	NCT03725761, SMPH-MEDICINE-HEM-ONC	University of Wisconsin
Sacituzumab govitecan, rucaparib	Solid tumours	I/II	Recruiting	USA	NCT03992131, CO338-098, SEASTAR	Clovis Oncology
Sacituzumab govitecan	Solid tumours	II	Halted due to COVID 19	USA	NCT03964727, Immu132-11, TROPICS-03	Immunomedics
Sacituzumab govitecan ± pembrolizumab	Urothelial cancer	II	Recruiting	Multinational	NCT03547973, IMMU132-06, TROPHY U-01	Immunomedics
Sacituzumab govitecan	Brain metastases, glioblastoma	I	Recruiting	USA	NCT03995706, CTMS19-0069, HSC20190378H	The University of Texas Health Science Center at San Antonio

HR + hormone receptor-positive, HER2– human epidermal growth factor receptor 2-negative, mBC metastatic breast cancer, mTNBC metastatic breast cancer triple-negative breast cancer